「high-risk」の検索結果

Select complementary review lenses for a requested multi-perspective review or a high-risk GEODE change. Covers design, agent constraints, gateway operations, and CLI/tool behavior; not a mandatory four-agent gate for ordinary edits.

日本語の概要は準備中です。原文の説明を表示しています。

欧盟 AI 法案知识引擎——以 70 份官方欧盟来源文件为基础的权威监管问答（包括 2026 年委员会关于 Art. 6 高风险分类的指南草稿——一般原则、附件 I、附件 III）。基于完整条例文本、委员会指南、EDPB/EDPS 意见、《实践守则》、协调标准、FRIA 指南、事件模板和行业特定指引，以条款级引用回答关于 AI 法案的任何问题。当用户询问"EU AI Act"、"AI Act regulation"、"Regulation 2024/1689"、"KI-Verordnung"、要求"explain an AI Act article"、"what does Article X say"、"AI Act requirements"、"AI Act penalties"、"AI Act timeline"、"GPAI obligations"、"high-risk AI"、"prohibited AI practices"、"AI Act and GDPR"、"fundamental rights impact assessment"、"AI Act standards"、"AI Act national implementation"、"AI literacy"、"serious incident reporting"、"Digital Omnibus"、"AI regulatory sandbox"，或任何关于欧盟人工智能监管的问题时，应使用本技能。德语术语同样触发："KI-Gesetz"、"KI-Verordnung"、"Hochrisiko-KI"、"KI-Kompetenz"、"Grundrechte-Folgenabschaetzung"、"GPAI-Verhaltenskodex"。对于产出分类决定而非知识答案的评估工作流，提议在会话内运行结构化风险等级分类。

日本語の概要は準備中です。原文の説明を表示しています。

Suggests initiating inpatient CGM for select diabetic patients at high risk for hypoglycemia based on Table 3 criteria. Triggers include "Should I initiate CGM for this hospitalized diabetic patient at high risk for hypoglycemia?" or "Is inpatient CGM warranted for this patient?"

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests using real-time continuous glucose monitoring (CGM) rather than no CGM for outpatients with type 2 diabetes (T2D) who take insulin and/or sulfonylureas and are at high risk for hypoglycemia. It is triggered by clinician questions such as "Should I use CGM for this T2D patient on insulin or sulfonylureas with high hypoglycemia risk?" or "Is CGM indicated for this patient?"

日本語の概要は準備中です。原文の説明を表示しています。

Recommends real-time CGM with confirmatory bedside POC-BG monitoring for insulin dosing adjustments rather than POC-BG testing alone in adults with insulin-treated diabetes at high risk of hypoglycemia. Consider this approach for patients aged ≥65 years, BMI ≤27 kg/m², total daily insulin dose ≥0.6 units/kg, CKD stage ≥3, or recent hypoglycemia.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests initiating inpatient continuous glucose monitoring (CGM) for select hospitalized patients at high risk for hypoglycemia, combined with periodic point-of-care glucose checks for accuracy. Triggers include planning glucose monitoring for inpatients with prior severe hypoglycemia, renal or hepatic dysfunction, or age 65 years or older.

日本語の概要は準備中です。原文の説明を表示しています。

Use when you need CRAP score and coverage risk analysis to find high-risk code before refactoring or release. Keywords: CRAP score, risk hotspots, cyclomatic complexity, test coverage gaps, coverage threshold.

日本語の概要は準備中です。原文の説明を表示しています。

Use when work produces a deliverable, factual claim, dataset, code change, decision, publication, deployment, automation, or irreversible action whose failure would matter; when the user asks for a quality gate, acceptance criteria, QA, completeness, validation, audit, evidence, preflight, release readiness, or a definition of done; or before claiming completion on medium- or high-risk work. Automatically decide whether a formal gate is warranted, derive task-specific pass/fail criteria, gather evidence, and block unsupported completion. Make sure to use this skill even when the user does not say "quality gate" if consequential work needs acceptance criteria or completion evidence. Skip formal gating for trivial, reversible, low-impact requests.

日本語の概要は準備中です。原文の説明を表示しています。

Integration review after stable code. Audit tier for high-risk surfaces; planning tier for optional low-risk review. Produces a review note and fix list — no implementation.

日本語の概要は準備中です。原文の説明を表示しています。

Knowledge base from EU Artificial Intelligence Act — Regulation (EU) 2024/1689. Use for AI system classification (high-risk vs prohibited vs general), conformity assessment procedures, GPAI model obligations, transparency and disclosure requirements, governance structure (AI Office / AI Board), penalty tiers, value-chain operator obligations, post-market monitoring, and Annex III use-case analysis. Does not cover EU liability rules for AI (separate proposed directive) or implementation guidance documents issued after July 2024.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates design workflows by routing work through brainstorming, multi-agent review, and execution readiness in the correct order. Prevents premature implementation, skipped validation, and unreviewed high-risk designs.

日本語の概要は準備中です。原文の説明を表示しています。

Run a bounded red-green-refactor feedback loop only when the user explicitly requests TDD, accepts reproduction-first proof for a bug, or an accepted high-risk behavior specifically requires red/green evidence; do not trigger for every logic, bug, behavior, or implementation change.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates design workflows by routing work through brainstorming, multi-agent review, and execution readiness in the correct order. Prevents premature implementation, skipped validation, and unreviewed high-risk designs.

日本語の概要は準備中です。原文の説明を表示しています。